East Timor Technology Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on East Timor Technology Press.

Press releases published on May 21, 2026

May 21, 2026

Audiencerate: Riccardo Fabbri wird Chief Technology Officer. Die KI-gesteuerte Phase der Plattformen für KMU und Medienagenturen beginnt

Indeterminate GlobeNewswire

May 21, 2026

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Indeterminate GlobeNewswire

May 21, 2026

Samba TV Launches Project Gravity, an Independent Data Activation Platform for the Agentic Era

Indeterminate GlobeNewswire

May 21, 2026

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Indeterminate GlobeNewswire

May 21, 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Indeterminate GlobeNewswire

May 21, 2026

Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing Season

Indeterminate GlobeNewswire

May 21, 2026

Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026

Indeterminate GlobeNewswire

May 21, 2026

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Indeterminate GlobeNewswire

May 21, 2026

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Indeterminate GlobeNewswire

May 21, 2026

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire

May 21, 2026

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Indeterminate GlobeNewswire

May 21, 2026

Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting

Indeterminate GlobeNewswire

May 21, 2026

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

Indeterminate GlobeNewswire

May 21, 2026

Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

Indeterminate GlobeNewswire

May 21, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 21, 2026

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 21, 2026

PacBio to Participate in the Jefferies Global Healthcare Conference 

Indeterminate GlobeNewswire

May 21, 2026

Zscaler to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 21, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

May 21, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire